Bessemer Group’s Cellebrite CLBT Stock Holding History

Bessemer Group’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-900	Closed	-$16K	–	2517
2025 Q4	$16K	Buy	+900	New	+$16.2K	﹤0.01%	1948

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bessemer Group's CLBT Position: Q1 2026 in Review

Bessemer Group sold out of Cellebrite (CLBT) in Q1 2026, closing a stake of 900 shares — an estimated $16K sold.

Bessemer Group first reported a position in CLBT in Q4 2025 and held it in 1 quarter. The position peaked at $16K in Q4 2025. 221 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

Bessemer Group reported no remaining Cellebrite position as of Q1 2026 after selling out during the quarter.
Bessemer Group sold 900 Cellebrite shares in Q1 2026, an estimated $16K.
Bessemer Group first reported a position in Cellebrite in Q4 2025 and held it in 1 quarter.
Bessemer Group's Cellebrite position peaked at $16K in Q4 2025.
221 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.